Insider Trading April 17, 2026 07:27 PM

Aehr Test Systems VP Disposes $163,760 in Shares as Stock Nears 52-Week High

Executive sale coincides with record production order and mixed quarterly results as analysts tweak targets

By Marcus Reed AEHR
Aehr Test Systems VP Disposes $163,760 in Shares as Stock Nears 52-Week High
AEHR

Alistair N Sporck, vice president of the Contactor Business Unit at Aehr Test Systems (NASDAQ:AEHR), sold 2,000 shares on April 16, 2026, generating $163,760. The transaction comes while the stock trades close to a 52-week peak after a 937% year-over-year gain. The company also reported a record $41 million production order from a hyperscale customer, mixed Q3 2026 financials, and strong bookings that prompted analyst price-target adjustments.

Key Points

  • Alistair N Sporck sold 2,000 Aehr Test Systems shares on April 16, 2026, at $81.88 each, totaling $163,760; he continues to hold 20,635 shares directly and 7,177 indirectly via trust.
  • Aehr Test Systems received a record $41 million production order from a hyperscale customer for package-level burn-in of custom AI processor ASICs, with deliveries slated to start in fiscal 2027.
  • Q3 2026 results were mixed - EPS of -$0.05 beat the -$0.07 forecast while revenue of $10.3 million missed the $10.8 million estimate; bookings hit a record $37.2 million, producing an effective backlog above $50 million.

Alistair N Sporck, who serves as vice president of the Contactor Business Unit at Aehr Test Systems (NASDAQ:AEHR), completed a sale of 2,000 shares of common stock on April 16, 2026. The shares traded at $81.88 apiece, producing a total transaction value of $163,760.

At the time of the sale the company's stock was trading near its 52-week high of $91.43, having climbed roughly 937% over the prior 12 months. After the disposal Sporck retains direct ownership of 20,635 shares, a total that the company notes includes shares tied to unvested restricted stock units. Separately, he has indirect holdings of 7,177 shares held by a trust.

Market commentary reflected in InvestingPro analysis characterizes AEHR as appearing overvalued at current prices despite the momentum in the share performance. The same analysis points to broader coverage through detailed Pro Research Reports that span more than 1,400 U.S. equities for investors seeking additional research.


On the corporate operations front, Aehr Test Systems announced it secured a record production order worth $41 million from a hyperscale customer. The order, identified as the largest in the company’s history, is for package-level burn-in of custom AI processor ASICs and includes Sonoma high-power package-level test and burn-in systems. The company expects deliveries under that order to commence in fiscal 2027.

Financial results for Q3 2026 were mixed. Reported earnings per share came in at negative $0.05, which beat the forecast of negative $0.07. Revenue for the quarter was $10.3 million, however, falling short of the $10.8 million analysts had expected. Despite the revenue shortfall, Aehr reported record quarterly bookings of $37.2 million, which the company said produced an effective backlog in excess of $50 million.

Analyst reactions have included adjustments to price targets while maintaining prior ratings. Freedom Broker increased its target to $61 from $38 and kept a Hold rating. Lake Street lifted its target to $56 from $50 and maintained a Buy rating. Both firms cited strong bookings momentum as a supporting factor.

These developments - an insider sale, the record production order for AI processor burn-in systems, mixed quarterly results, robust bookings and subsequent analyst target changes - underline active investor and market interest in Aehr Test Systems. Observers seeking further valuation context are directed to the detailed research coverage noted in market analysis tools.

Risks

  • Valuation concerns - InvestingPro analysis indicates AEHR appears overvalued at current share levels despite strong momentum, posing market risk for investors.
  • Execution and timing risk - the large $41 million production order has deliveries beginning in fiscal 2027, which ties future revenue realization to delivery schedules and customer execution.
  • Revenue variability - Q3 2026 revenue missed expectations despite better-than-expected EPS, highlighting potential volatility in top-line performance that could affect investor sentiment.

More from Insider Trading

OrbiMed Expands Stake in Traws Pharma via Strategic Private Placement Apr 28, 2026 Rexford Industrial Realty General Counsel Completes $1.18 Million Stock Sale Apr 28, 2026 Bicara Therapeutics CMO Executes Rule 10b5-1 Trading Plan Involving Share Sales and Option Exercises Apr 28, 2026 Abbott Laboratories Director Daniel Starks Executes Substantial Open Market Share Purchase Apr 28, 2026 BlackRock President Robert Kapito Executes $9.2 Million Share Sale Apr 28, 2026